Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak

Authors

Stringhini S, Zaballa ME, Perez-Saez J, Pullen N, de Mestral C, Picazio A, Pennacchio F, Wisniak A, Richard A, Baysson H, Loizeau A, Balavoine JF, Trono D, Pittet D, Posfay-Barbe K, Flahault A, Chappuis F, Kherad O, Vuilleumier N, Kaiser L, Azman AS, Guessous I, Specchio-COVID19 Study Group

Journal

Lancet Infect Dis

Volume

Pages

Publication year

2021

Suggested citation

Stringhini S, Zaballa ME, Perez-Saez J, Pullen N, de Mestral C, Picazio A, Pennacchio F, Wisniak A, Richard A, Baysson H, Loizeau A, Balavoine JF, Trono D, Pittet D, Posfay-Barbe K, Flahault A, Chappuis F, Kherad O, Vuilleumier N, Kaiser L, Azman AS, Guessous I, Specchio-COVID19 Study Group. Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak. Lancet Infect Dis. 2021.

DOI

10.1016/S1473-3099(21)00054-2

PMID

33539733

Header sites

Search form

Main menu

Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak

Nav